Zacks Research Has Bullish Forecast for CRL Q2 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) - Analysts at Zacks Research lifted their Q2 2026 EPS estimates for Charles River Laboratories International in a research note issued to investors on Monday, April 7th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $2.67 for the quarter, up from their previous forecast of $2.66. The consensus estimate for Charles River Laboratories International's current full-year earnings is $9.36 per share.

CRL has been the topic of several other reports. Robert W. Baird lowered their price target on Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. Citigroup upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their price target for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. Mizuho reduced their price objective on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research note on Wednesday, April 9th. UBS Group reiterated a "neutral" rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Finally, Redburn Atlantic raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective on the stock in a research report on Monday, March 3rd. One research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $182.00.

Remove Ads

Charles River Laboratories International Stock Performance

CRL traded up $5.83 during midday trading on Wednesday, hitting $105.58. 1,415,709 shares of the company traded hands, compared to its average volume of 861,054. The company's 50-day moving average is $156.71 and its 200 day moving average is $176.86. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $5.19 billion, a PE ratio of 703.87, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International has a 52 week low of $91.86 and a 52 week high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same quarter last year, the company earned $2.46 EPS. The company's quarterly revenue was down 1.1% compared to the same quarter last year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CRL. Patriot Financial Group Insurance Agency LLC lifted its holdings in shares of Charles River Laboratories International by 12.8% in the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 1,706 shares of the medical research company's stock worth $257,000 after acquiring an additional 194 shares during the last quarter. Impact Capital Partners LLC boosted its position in shares of Charles River Laboratories International by 12.2% during the first quarter. Impact Capital Partners LLC now owns 2,567 shares of the medical research company's stock valued at $386,000 after buying an additional 280 shares during the period. Veracity Capital LLC grew its stake in shares of Charles River Laboratories International by 3.4% during the first quarter. Veracity Capital LLC now owns 3,298 shares of the medical research company's stock valued at $496,000 after buying an additional 107 shares during the last quarter. Heritage Family Offices LLP raised its holdings in shares of Charles River Laboratories International by 10.0% in the first quarter. Heritage Family Offices LLP now owns 1,689 shares of the medical research company's stock worth $254,000 after buying an additional 153 shares during the period. Finally, Mitchell & Pahl Private Wealth LLC lifted its stake in shares of Charles River Laboratories International by 6.7% during the 1st quarter. Mitchell & Pahl Private Wealth LLC now owns 3,843 shares of the medical research company's stock worth $578,000 after acquiring an additional 240 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Charles River Laboratories International

In related news, CEO James C. Foster acquired 6,075 shares of the stock in a transaction dated Thursday, February 20th. The stock was acquired at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the purchase, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Birgit Girshick bought 1,514 shares of the business's stock in a transaction dated Thursday, February 20th. The shares were bought at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the transaction, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).